Corporate$IRON11:28 AM ET

Disc Medicine Stock Surges 35% as Drug Trial Revives FDA Approval Hopes

By BORSA NewsroomPublished Oct 19, 2026, 11:28 AM EDTUpdated Oct 19, 2026, 11:28 AM EDT

Disc Medicine (IRON) surged 35% after Phase 3 data for bitopertin met primary and secondary goals in erythropoietic protoporphyria. The company plans to resubmit an NDA by year-end, with a decision expected by mid-2027. Cantor Fitzgerald raised its probability-of-success model to 95%.

Sentimentbullish 85

Strongly bullish · 85 of 100

Impact70

medium · sector-wide

Confidence90%

high confidence · single wire

Eventdeveloping

v1 · alerts feed only

WHAT WE KNOW

Phase 3 trial met primary and secondary endpoints